Central Serous Chorioretinopathy Clinical Trial
Official title:
Selective Retina Therapy (SRT) in Patients With Idiopathic Central Serous Chorioretinopathy: A Prospective Randomized Controlled Trial
The purpose of this study is to evaluate the efficacy of Selective Retina Therapy (SRT) for
treating acute idiopathic central serous chorioretinopathy (ICSC). Patients with acute
symptomatic ICSC of at least 3 months duration were recruited. The patients were randomized
by equal terms to SRT- (Treatment) and control group. After 3 months follow up patients of
control group with persistence of disease activity were allocated to crossover group and
received either SRT. Crossover group was followed up for further 3 months.
The primary outcome measure of the study are the serial changes in Early Treatment of
Diabetic Retinopathy Study (ETDRS) letterscore and edema in optical coherence tomography
(OCT) at 3 months. Secondary outcome measures included the proportion of eyes with complete
absorption of subretinal fluid, leakage in fluorescein angiography and the systemic and
ocular complications during the study at 3 months.
Idiopathic central serous chorioretinopathy (ICSC) is characterized by a serous detachment
of the neurosensory retina in the macular region secondary to a focal or retinal pigment
epithelial defect. Patients with ICSC, oftentimes young male adults, experience visual
disturbances including micropsia, metamorphopsia, central scotoma, reduced visual acuity and
loss of contrast sensitivity. Most cases of ICSC are presumed to be self-limiting and
usually resolve spontaneously within 3 to 4 months.Nevertheless the duration of the disease
is strongly related to the vision prognosis and reattachment within 4 months of onset is
considered as a relevant therapeutic target because prolonged detachment is associated with
photoreceptor atrophy.
The therapeutic effect of focal cw laser photocoagulation has not been fully established.
One obvious theory postulates that the beneficial effect of photocoagulation is associated
with the establishment of a new barrier of RPE cells which subsequently reintegrate the RPE
pump function and the integrity of the RPE as a barrier. Based on this theory, the
destruction of tissues surrounding the RPE, in particular Bruch`s membrane, the choroid and
the photoreceptors, would be an unwanted side effect. On the basis of this consideration
Selective Retina Therapy (SRT), which is a innovative laser technology that selectively
damages the RPE and spares the neurosensory retina, suggests itself as an ideal treatment
for ICSC with focal leakage, especially if the RPE leak is located close to the fovea.
It has been proved as safe, and microperimetry has shown that SRT does not cause
microscotoma. SRT has already been adopted in the treatment of diverse macular diseases
inter alia in patients with ICSC with promising performance.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03497000 -
Effects of OCTA-guided PDT in Acute CSC
|
N/A | |
Recruiting |
NCT03692169 -
The Changes of Retinal Capillaries After Half-dose PDT Measured by OCTA in Eyes With CSC
|
||
Not yet recruiting |
NCT02215330 -
A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy
|
Phase 2/Phase 3 | |
Completed |
NCT01990677 -
Eplerenone for the Treatment of Central Serous Chorioretinopathy
|
N/A | |
Completed |
NCT01971190 -
Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy
|
Phase 2 | |
Active, not recruiting |
NCT01710332 -
The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
|
Phase 2 | |
Active, not recruiting |
NCT00403884 -
Selective RPE Laser Treatment (SRT) for Various Macular Diseases
|
N/A | |
Recruiting |
NCT05570591 -
Subthreshold Nanosecond Laser for Non-resolving Central Serous Chorioretinopathy
|
N/A | |
Recruiting |
NCT05589974 -
Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy
|
||
Completed |
NCT05104138 -
Eplerenone Versus PDT: Comparative Study by OCTA
|
||
Terminated |
NCT01982383 -
Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy
|
N/A | |
Completed |
NCT01880788 -
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
|
N/A | |
Completed |
NCT01327170 -
Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy
|
N/A | |
Completed |
NCT01019668 -
Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy
|
N/A | |
Recruiting |
NCT06346405 -
Central Serous Chorioretinopathy and Micropulse Laser Treatment
|
||
Recruiting |
NCT02141308 -
OCT in Rare Chorioretinal Diseases
|
||
Completed |
NCT01822561 -
Eplerenone for Central Serous Chorioretinopathy
|
Phase 2 | |
Completed |
NCT00802906 -
Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)
|
N/A | |
Withdrawn |
NCT05679180 -
Navigated Microsecond Laser for Chronic Central Serous Chorioretinopathy: MICROPULSE
|
N/A | |
Completed |
NCT05686421 -
Comfortable and Stabilizing Chin & Forehead Rest Attachment for Slit Lamp Configurations
|
N/A |